AstraZeneca plc (AZN) Ordinary US$0.25
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
- Add to watchlist
- Create an alert
- This stock can be held in a
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
Share news, reports & tips
-
AstraZeneca posts mixed results from recent Imfinzi trials
25 June 2024 07:17
(Sharecast News) - AstraZeneca announced contrasting results from two phase three trials involving its immunotherapy drug 'Imfinzi', or durvalumab, on Tuesday.
-
AstraZeneca trial fails to treat 'challenging' breast cancer
18 June 2024 07:17
(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary...
-
AstraZeneca's Imfinzi gets US approval for endometrial cancer patients
17 June 2024 07:15
(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.
-
London pre-open: Stocks set for lower start after EU elections
10 June 2024 06:25
(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were...
-
AstraZeneca's lung cancer treatment recommended for approval in EU
3 June 2024 07:28
(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.
-
AstraZeneca experimental lung cancer drug shows promising results
28 May 2024 07:02
(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.
-
Sector movers: Stocks slip amid light profit-taking
21 May 2024 19:00
(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.
-
London close: Stocks fall ahead of key inflation reading
21 May 2024 15:00
(Sharecast News) - London stocks ended in negative territory on Tuesday, influenced by the latest UK economic outlook from the International Monetary Fund (IMF) and comments from US Federal Reserve officials.
-
AstraZeneca lays out plans to hit $80bn in revenues by 2030
21 May 2024 07:34
(Sharecast News) - AstraZeneca has unveiled medium-term growth targets to nearly double group revenues by the end of the decade as it predicts significant growth from existing oncology, biopharmaceuticals...
-
AstraZeneca announces $1.5bn Singapore manufacturing facility
20 May 2024 07:22
(Sharecast News) - AstraZeneca announced plans to construct a $1.5bn manufacturing facility in Singapore on Monday, dedicated to the production of antibody drug conjugates (ADCs).
-
Sector movers: Aerospace and Defence, Pharma pace gains
8 May 2024 19:10
(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.
-
London close: Stocks rise further ahead of BoE decision
8 May 2024 16:36
(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.
Company announcements Announcements
-
Update on Imfinzi ADJUVANT BR.31 trial
25 June 2024 07:05
AstraZeneca
-
Imfinzi improved EFS and OS in bladder cancer
25 June 2024 07:00
AstraZeneca
-
Update on CAPItello-290 Phase III trial
18 June 2024 07:00
AstraZeneca
-
Imfinzi approved in the US for endometrial cancer
17 June 2024 07:00
AstraZeneca
-
Director/PDMR Shareholding
12 June 2024 15:00
AstraZeneca
-
Acquisition of Fusion completed
5 June 2024 07:00
AstraZeneca
-
Block listing Interim Review
3 June 2024 15:05
AstraZeneca
-
Total Voting Rights
3 June 2024 15:00
AstraZeneca
-
Tagrisso plus chemo recommended for approval in EU
3 June 2024 07:00
AstraZeneca
-
Dato-DXd improved OS in nonsquamous lung cancer
28 May 2024 07:00
AstraZeneca
-
AstraZeneca to deliver $80bn revenue by 2030
21 May 2024 07:00
AstraZeneca
-
AstraZeneca to manufacture ADCs in Singapore
20 May 2024 07:00
AstraZeneca
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.